- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03729791
The Effect of tDCS on Schizophrenia With Negative Symptoms
Clinical Trials for Neuroimaging and Electrophysiology in Schizophrenic Patients With Negative Symptoms Using Transcranial Direct Current Stimulation
Visão geral do estudo
Descrição detalhada
The project will investigate the use of a novel technique, transcranial direct current stimulation (tDCS) in the treatment of patients with schizophrenia. tDCS permit the application of an extremely weak continuous electrical current to the brain through an anode and a cathode applied on the scalp. Anodal stimulation appears to increase brain activity whereas cathodal stimulation has the opposite effect.
Using anodal and cathodal tDCS the investigators aimed to treat negative symptoms of schizophrenia. The investigators plan to apply tDCS such that it can simultaneously increased activity in the frontal brain areas and reduce activity over temporoparietal cortex, 2 areas involved in the physiopathology of the disease. Real active stimulation will be compare to a sham condition in 44 patients (22 in each group). 44 patients will be included in Seoul National University Hospital
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Seoul, Republica da Coréia
- Seoul National University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- DSM-IV Schizophrenia
- 1 or more items of Negative symptom score in PANSS > 5
Exclusion Criteria:
- presences of neurological disorder or history
- IQ < 70
- presence of severe personality disorders
- presence of substance use disorder (except nicotin)
- pregnancy
- presence of severe medical condition or disorders
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: actual tDCS
2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
|
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head.
It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
|
Comparador Ativo: sham tDCS
sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
|
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head.
It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Positive and Negative Syndrome Scale (PANSS)
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in psychopathology To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted.
The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
The Clinical Assessment Interview for Negative Symptoms (CAINS)
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in psychopathology The CAINS is a clinical rating scale for negative symptoms with potent and clear treatment targets for the next generation of pharmacological and psychosocial treatments.
It rangs between 0 to 52
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - resting
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in lagged phase synchronization and microstate connectivity
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - P300
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in P300
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - MMN
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MMN
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - ERN
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in ERN
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - grey matter volume
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in grey matter volume
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical thickness
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in cortical thickness
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical surface area
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MRI - cortical thickness
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical gyrification
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in cortical gyrification
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - mean diffusivity (MD)
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - axial diffusivity (AD)
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in AD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - radial diffusivity (RD)
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in RD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - fractional anisotropy (FA)
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in FA
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - rsfMRI
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in BOLD signals
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - MRS
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
Changes in concentration of N-Acetyl Aspartate, Creatin, Choline, Myoinositol, Glutamate, Glutamine, GABA metabolite concentration change with treatment
|
approximately 2 weeks (baseline and 2 weeks followups)
|
fNIRS
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
change in level of the Oxy-Hemoglobin
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Korean Wechsler Adult Intelligence Scale (K-WAIS)
Prazo: baseline
|
baseline total Intelligence quotient value
|
baseline
|
Spatial Working Memory
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in the spatial working memory ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
California Verbal Learning Test
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in verbal learning ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Letter/Category fluency test
Prazo: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in fluency ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Tae Young Lee, MD, Seoul National University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Antecipado)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1.001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em tDCS
-
Nova Southeastern UniversitySurgical Specialists of MiamiConcluído
-
Centre Hospitalier Universitaire de NiceRetirado
-
National Cancer Institute (NCI)RecrutamentoNeoplasias | Tumores SólidosEstados Unidos
-
Northwestern UniversityAtivo, não recrutandoNarcolepsia | Narcolepsia Tipo 1 | Narcolepsia Sem Cataplexia | Narcolepsia com Cataplexia | Narcolepsia tipo 2Estados Unidos
-
University of OklahomaVA Office of Research and DevelopmentRescindidoIsquemia Cerebral | Infarto CerebralEstados Unidos
-
University of PennsylvaniaTeleflex; Arrow InternationalConcluídoInsuficiência Renal Crônica Requerendo Hemodiálise | Insuficiência Renal CrônicaEstados Unidos
-
Abant Izzet Baysal UniversityThe Scientific and Technological Research Council of TurkeyRetiradoCâncer de mama | LinfedemaPeru
-
University of SalamancaRecrutamentoEdema Linfático | Celulite da perna | Doença venosaEspanha
-
Nova Southeastern UniversityConcluídoPerfusão; Complicações | Tecido de Retenção de LíquidosEstados Unidos
-
Roswell Park Cancer InstituteRetiradoCarcinoma de Próstata Resistente à Castração | Câncer de Próstata Estágio IV AJCC v8 | Câncer de Próstata Estágio IVA AJCC v8 | Câncer de Próstata Estágio IVB AJCC v8 | Progressão do PSA | Carcinoma de Próstata Metastático em Partes Moles | Níveis de castração de testosterona | Carcinoma de próstata... e outras condiçõesEstados Unidos